Neurovascular Defects and Faulty Amyloid-β Vascular Clearance in Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
The evidence that neurovascular dysfunction is an integral part of Alzheimer's disease (AD) pathogenesis has continued to emerge in the last decade. Changes in the brain vasculature have been shown to contribute to the onset and progression of the pathological processes associated with AD, such as microvascular reductions, blood brain barrier (BBB) breakdown, and faulty clearance of amyloid β-peptide (Aβ) from the brain. Herein, we review the role of the neurovascular unit and molecular mechanisms in cerebral vascular cells behind the pathogenesis of AD. In particular, we focus on molecular pathways within cerebral vascular cells and the systemic circulation that contribute to BBB dysfunction, brain hypoperfusion, and impaired clearance of Aβ from the brain. We aim to provide a summary of recent research findings implicated in neurovascular defects and faulty Aβ vascular clearance contributing to AD pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 1×
“It plays an important role in lipoprotein transport and cholesterol homeostasis [147].”
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 2×
“Earlier genetic studies have suggested that LRP1 is linked to AD and CAA [87–90], but this has not been confirmed by later studies [91, 92].”
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 2×
“The neurovascular unit (NVU) consists of different cell types including (i) vascular cells such as brain endothelial cells lining the cerebral vascular tree, pericytes covering microvascular capillaries, and vascular smooth muscle cells (VSMCs) enwrapping cerebral arterioles and arteries, (ii) glial cells such as astr…”
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Pericytes regulate the blood–brain barrier
Armulik, A., Genové, G., Mäe, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., He, L., Norlin, J., Lindblom, P., Strittmatter, K., et al. (2010) · Nature · doi:10.1038/nature09522 · Cited by 2,843 · cited 2×
“Studies using transgenic mouse models of pericyte deficiency generated by PDGF-B and/or PDGFRβ deficiency have shown that brain pericytes are essential safeguards of the BBB [25-27] contributing to BBB formation during development and BBB maintenance in the adult brain [20, 26].”
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“…of amyloid (cid:1) -peptide (A (cid:1) ) in the brain parenchyma and around cerebral blood vessels [1], intraneuronal tau-related lesions [2, 3], and neurovascular dysfunction specific cellular and molecular mechanisms the neurovascular unit and at the blood-brain In this review, we will…”
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012
The Science of Stroke: Mechanisms in Search of Treatments
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010) · Neuron · doi:10.1016/j.neuron.2010.07.002 · Cited by 1,930
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 1×
“How apoE4 influences onset and progression of AD is not completely understood [51, 53, 151].”
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
miR-145 and miR-143 regulate smooth muscle cell fate and plasticity
Cordes, K. R., Sheehy, N. T., White, M. P., Berry, E. C., Morton, S. U., Muth, A. N., Lee, T.-H., Miano, J. M., Ivey, K. N., & Srivastava, D. (2009) · Nature · doi:10.1038/nature08195 · Cited by 1,585
Bell, R. D., Winkler, E. A., Sagare, A. P., Singh, I., LaRue, B., Deane, R., & Zlokovic, B. V. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.043 · Cited by 1,448 · cited 5×
“Moreover, recent studies have shown that pericyte loss caused by faulty PDGF-B signal transduction from endothelium to PDGFRβ in pericytes leads to BBB breakdown, CBF reductions and hypoxia which in turn initiates age-dependent secondary neuronal and synaptic changes associated with neuronal and synaptic dysfunction […”
InfluentialSelf-citationShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“Reduced LRP1 levels in brain microves-sels correlate with endogenous A deposition in a (cid:1) cerebrovascular and brain accumulation in AD patients [102, 120].”
Understanding RAGE, the receptor for advanced glycation end products
Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0688-7 · Cited by 1,297 · cited 1×
“Interaction of ligands with RAGE activates signal transduction pathways leading to increased cellular stress as seen in chronic diseases such as diabetes, inflammation and AD [137-139].”
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A
Bell, R. D., Winkler, E. A., Singh, I., Sagare, A. P., Deane, R., Wu, Z., Holtzman, D. M., Betsholtz, C., Armulik, A., Sallstrom, J., et al. (2012) · Nature · doi:10.1038/nature11087 · Cited by 1,293 · cited 2×
“…growth factors including angioneurins [28], affecting health of the cerebrovascular Another recent example relates vascular damage BBB disruption mediated by apolipoprotein E4 APOE4), a major genetic risk factor for AD, which secondary neuronal dysfunction and neurodegenerative changes [29].”
Self-citationHuman ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Holtzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937 · cited 1×
“In addition to earlier described Aβ-independent pathway of apoE4-mediated vascular defects causing neuronal dysfunction and neurodegeneration [29], several studies have suggested that interaction of apoE with Aβ plays an important role in the pathogenesis of AD [70, 97, 106, 152-155].”
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
Apolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857 · cited 2×
“The efficiency of Aβ clearance from brain interstitial fluid across the BBB is influenced by Aβ binding transport proteins such as apoE and apoJ (clusterin), and BBB receptors such as LRP1, LRP2 and receptor for advanced glycation end products (RAGE) which control Aβ efflux from brain and influx into the brain, respec…”
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Self-citationApolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid
Wisniewski, T., & Frangione, B. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90444-c · Cited by 802 · cited 1×
“How apoE4 influences onset and progression In addition to earlier described A (cid:1) -independent pathway of apoE4-mediated vascular defects causing several studies have suggested that interaction of with A (cid:1) plays an important role in the pathogenesis of AD [70, 97, 106, 152–155].”
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 8×
“In multiple animal models, we and others have shown that binding of A to LRP1 at the abluminal side of the BBB results in its rapid clearance into the blood [66, 70, 102, 106–112].”
InfluentialSelf-citationReview: Cerebral microvascular pathology in ageing and neurodegeneration
Brown, W. R., & Thore, C. R. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01139.x · Cited by 749 · cited 1×
“Several studies have reported that focal vascular regression and diminished microvascular density occur in AD [18, 30-32] as well as in AD transgenic mouse models [33].”
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · cited 8×
“In multiple animal models, we and others have shown that binding of A to LRP1 at the abluminal side of the BBB results in its rapid clearance into the blood [66, 70, 102, 106–112].”
InfluentialSelf-citationCirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660 · cited 1×
“In multiple animal models, we and others have shown that binding of A to LRP1 at the abluminal side of the BBB results in its rapid clearance into the blood [66, 70, 102, 106–112].”
Deane, R., Singh, I., Sagare, A. P., Bell, R. D., Ross, N. T., LaRue, B., Love, R., Perry, S., Paquette, N., Deane, R. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58642 · Cited by 619
Self-citationApolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides
Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1058 · Cited by 571 · cited 1×
“LRP1and/oranothermemberoftheLDLreceptorfam-ilyhavebeeninvolvedinapoE-dependentuptakeofA (cid:1) degradation by astrocytes [101].”
Demeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557 · cited 1×
“…RAP [103], tPA [104], lipid free and lipidated apoE2 apoE3 including their complexes with A (cid:1) [70], a family of Kunitz domain-derived peptides [105]. demonstrated that LRP1 has a key role in a three-step serial clearance mechanism mediating A (cid:1) elimination from arteries [37].”
RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease
Donahue, J. E., Flaherty, S. L., Johanson, C. E., Duncan, J. A., Silverberg, G. D., Miller, M. C., Tavares, R., Yang, W., Wu, Q., Sabo, E., et al. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0115-3 · Cited by 519
ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M., et al. (2004) · Neuron · doi:10.1016/s0896-6273(03)00850-x · Cited by 459 · cited 2×
“neuronal dysfunction and neurodegeneration [29], several studies have suggested that interaction of apoE with A plays an important role in the pathogenesis of AD [70, 97, 106, 152–155].”
Lipoprotein receptors in the nervous system
Herz, J., & Bock, H. H. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135342 · Cited by 457
Gotthardt, M., Trommsdorff, M., Nevitt, M. F., Shelton, J., Richardson, J. A., Stockinger, W., Nimpf, J., & Herz, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000955200 · Cited by 450 · cited 1×
“The cytoplasmic tail phosphorylated on serine and/or tyrosine residues [71, 72] interacts with different adaptor proteins associated with cell signaling such as disabled-1 (Dab1), FE65, and postsynaptic density protein 95 [58, 73, 74].”
Grammas, P. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-26 · Cited by 432 · cited 1×
“Several studies have reported that focal vascular regression and diminished microvascular density occur in AD [18, 30–32] as well as in AD transgenic mouse models [33].”
Yan, S. D., Yan, S. F., Chen, X., Fu, J., Chen, M., Kuppusamy, P., Smith, M. A., Perry, G., Godman, G. C., Nawroth, P., et al. (1995) · Nature Medicine · doi:10.1038/nm0795-693 · Cited by 406 · cited 2×
“RAGE expression is increased in both neurons and endothelium in an Aβ-rich or AGE-rich environment as in AD [142], which amplifies Aβ-mediated pathogenic responses.”
Sehgal, N., Gupta, A., Valli, R. K., Joshi, S. D., Mills, J. T., Hamel, E., Khanna, P., Jain, S. C., Thakur, S. S., & Ravindranath, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112209109 · Cited by 390 · cited 1×
“Enhancing expression of LRP1 in brain microvessels and liver and circulating sLRP1 in plasma using plant-derived pharmacologically active compounds from Withania somnifera resulted in rapid reversal of A pathology and improved cognitive function in A PP/PS1 transgenic mouse model of AD [130, 131].”
The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature
Yan, S. F., Ramasamy, R., & Schmidt, A. M. (2010) · Circulation Research · doi:10.1161/circresaha.109.212217 · Cited by 381
Proteolytic Degradation of Amyloid -Protein
Saido, T., & Leissring, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006379 · Cited by 368
Kang, D. E., Pietrzik, C. U., Baum, L., Chevallier, N., Merriam, D. E., Kounnas, M. Z., Wagner, S. L., Troncoso, J. C., Kawas, C. H., Katzman, R., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11013 · Cited by 354
Blood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model
UJIIE, M., DICKSTEIN, D. L., CARLOW, D. A., & JEFFERIES, W. A. (2003) · Microcirculation · doi:10.1038/sj.mn.7800212 · Cited by 351
Neurovascular signalling defects in neurodegeneration
Zacchigna, S., Lambrechts, D., & Carmeliet, P. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2336 · Cited by 345
RAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction
Takuma, K., Fang, F., Zhang, W., Yan, S., Fukuzaki, E., Du, H., Sosunov, A., McKhann, G., Funatsu, Y., Nakamichi, N., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905686106 · Cited by 290 · cited 1×
“In addition, intraneuronal A transport via RAGE leads to mitochondrial dysfunction [140].”
Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
Wu, Z., Guo, H., Chow, N., Sallstrom, J., Bell, R. D., Deane, R., Brooks, A. I., Kanagala, S., Rubio, A., Sagare, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1287 · Cited by 280
Self-citationWillnow, T. E., Rohlmann, A., Horton, J., Otani, H., Braun, J. R., Hammer, R. E., & Herz, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00623.x · Cited by 276 · cited 1×
“During biosynthesis of LRP1, the receptor-associated protein (RAP) acts as a chaperone for its proper folding [61].”
SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells
Bell, R. D., Deane, R., Chow, N., Long, X., Sagare, A., Singh, I., Streb, J. W., Guo, H., Rubio, A., Van Nostrand, W., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1819 · Cited by 261 · cited 6×
“In addition, it has been shown that increased levels of MYOCD and SRF in AD VSMCs also suppress Aβ clearance directly thus further exacerbating CAA [37].”
InfluentialSelf-citationZlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261
Self-citationThe Low Density Lipoprotein Receptor-related Protein (LRP) Is a Novel β-Secretase (BACE1) Substrate
von Arnim, C. A. F., Kinoshita, A., Peltan, I. D., Tangredi, M. M., Herl, L., Lee, B. M., Spoelgen, R., Hshieh, T. T., Ranganathan, S., Battey, F. D., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414248200 · Cited by 258 · cited 1×
“Cell surface levels and function of LRP1 are controlled by proteolytic shedding of its ectodomain [77–82].”
Neurovascular Dysfunction and Faulty Amyloid -Peptide Clearance in Alzheimer Disease
Sagare, A. P., Bell, R. D., & Zlokovic, B. V. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011452 · Cited by 251
Self-citationMackic, J. B., Stins, M., McComb, J. G., Calero, M., Ghiso, J., Kim, K. S., Yan, S. D., Stern, D., Schmidt, A. M., Frangione, B., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2029 · Cited by 242 · cited 1×
“the BBB, RAGE mediates transport of circulating A into the brain [49, 143] which results in NF-κ neu-roinflammatory response, on one hand, and generation endothelin-1 suppressing the CBF, on the other [49]. initiates cellular signaling leading to monocyte traf-ficking traf-ficking across the BBB [144].”
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237 · cited 1×
“Recent genome-wide association studies identified clusterin gene (CLU) as one of the risk factor for AD [91, 92, 160–166].”
Giri, R., Shen, Y., Stins, M., Du Yan, S., Schmidt, A. M., Stern, D., Kim, K.-S., Zlokovic, B., & Kalra, V. K. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.279.6.c1772 · Cited by 218
Distribution of clusterin in Alzheimer brain tissue
McGeer, P. L., Kawamata, T., & Walker, D. G. (1992) · Brain Research · doi:10.1016/0006-8993(92)90071-g · Cited by 212 · cited 1×
“ApoJ is expressed at high levels in the brain and found associated with senile plaques in AD [159].”
Chow, N., Bell, R. D., Deane, R., Streb, J. W., Chen, J., Brooks, A., Van Nostrand, W., Miano, J. M., & Zlokovic, B. V. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608251104 · Cited by 209 · cited 4×
“A growing number of essential VSMCrestricted cyto-contractile genes and genes regulating Ca2+ flux are downstream targets of SRF-MYOCD such as taglin, smooth muscle alpha actin, calponin and myosin heavy chain, sacroplasmic/endoplasmic reticulum calcium ATPase2, calsequestrin 1, myosin light chain kinase, and the miRN…”
InfluentialSelf-citationReplication of CLU, CR1, and PICALM Associations With Alzheimer Disease
Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Dickson, D. W., Graff-Radford, N. R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.147 · Cited by 208 · cited 1×
“Recent genome-wide association studies (GWAS) identified clusterin gene (CLU) as one of the risk factor for Alzheimer’s disease [91, 92, 160-166].”
Hippocampal RAGE immunoreactivity in early and advanced Alzheimer’s disease
Miller, M. C., Tavares, R., Johanson, C. E., Hovanesian, V., Donahue, J. E., Gonzalez, L., Silverberg, G. D., & Stopa, E. G. (2008) · Brain Research · doi:10.1016/j.brainres.2008.06.124 · Cited by 194 · cited 2×
“An increased RAGE expression in brain endothelium has been shown in advanced AD compared to early stage AD and/or individuals with mild cognitive impairment (MCI) [125].”
Lee, J. H., Cheng, R., Barral, S., Reitz, C., Medrano, M., Lantigua, R., Jiménez-Velazquez, I. Z., Rogaeva, E., St. George-Hyslop, P. H., & Mayeux, R. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.292 · Cited by 190 · cited 1×
“Recent genome-wide association studies identified clusterin gene (CLU) as one of the risk factor for AD [91, 92, 160–166].”
Evidence of angiogenic vessels in Alzheimer’s disease
Desai, B. S., Schneider, J. A., Li, J.-L., Carvey, P. M., & Hendey, B. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0226-9 · Cited by 153 · cited 1×
“Some studies have suggested presence of isolated areas of increased focal vascularity in AD brains [36] further supporting a concept that abnormalities in brain angiogenesis are implicated in AD pathogenesis.”
Martel, C. L., Mackic, J. B., Matsubara, E., Governale, S., Miguel, C., Miao, W., McComb, J. G., Frangione, B., Ghiso, J., & Zlokovic, B. V. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69051995.x · Cited by 149
Zerbinatti, C. V., Wozniak, D. F., Cirrito, J., Cam, J. A., Osaka, H., Bales, K. R., Zhuo, M., Paul, S. M., Holtzman, D. M., & Bu, G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305803101 · Cited by 133 · cited 1×
“LRP1 also mediates A neuronal uptake via 2 M and apoE [70, 95–99].”
Cytoprotective protein C pathways and implications for stroke and neurological disorders
Zlokovic, B. V., & Griffin, J. H. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.01.005 · Cited by 128 · cited 1×
“Alterations in the physiological signal transduction pathways between different cell types within the NVU has been increasingly recognized as an important factor which may contribute to disease initiation and progression in multiple neurological disorders [8, 9, 17, 18, 20-24].”
Tamaki, C., Ohtsuki, S., Iwatsubo, T., Hashimoto, T., Yamada, K., Yabuki, C., & Terasaki, T. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0208-7 · Cited by 119
Tamaki, C., Ohtsuki, S., & Terasaki, T. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.036913 · Cited by 111
Kinetics of arginine-vasopressin uptake at the blood-brain barrier
Zlokovic, B. V., Hyman, S., McComb, J. G., Lipovac, M. N., Tang, G., & Davson, H. (1990) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(90)90097-8 · Cited by 98 · cited 1×
“are expressed at the BBB [15, 16].”
Mann, G. E., Zlokovic, B. V., & Yudilevich, D. L. (1985) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(85)90179-8 · Cited by 84
Cited by
Clearance systems in the brain—implications for Alzheimer disease
Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B. V., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.119 · Cited by 1,678
Post-Stroke Cognitive Impairment and Dementia
Rost, N. S., Brodtmann, A., Pase, M. P., van Veluw, S. J., Biffi, A., Duering, M., Hinman, J. D., & Dichgans, M. (2022) · Circulation Research · doi:10.1161/circresaha.122.319951 · Cited by 790
Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease
Nelson, A. R., Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.12.016 · Cited by 559
Self-citationDaulatzai, M. A. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23777 · Cited by 429
Kerner, N. A., & Roose, S. P. (2016) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.01.134 · Cited by 331
Metadata
- Authors
- Sagare, A. P., Bell, R. D., & Zlokovic, B. V.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2012-12-27
- Volume
- 33
- Issue
- s1
- Pages
- S87-S100
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1540257283
- Cited by
- 140
- References
- 70
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.